In a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic ...

Cidara Therapeutics Inc. will meet with the FDA to discuss strongly favorable phase IIb results from its randomized, ...

In recognition of the fact that diversity, equity and inclusion (DEI) are necessary prerequisites for precision medicine, the ...

At the American Diabetes Association 85th Scientific Sessions in Chicago June 20-23, Fractyl Health Inc. presented results ...

Transthera Sciences Inc. debuted on the Hong Kong stock exchange June 23 with a HK$200.95 million (US$25.6 million) IPO, becoming the latest in a string of mainland Chinese biopharmaceutical firms to ...

Archeus Technologies Inc. has obtained IND clearance from the FDA for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.

Therapies against aggressive T-cell lymphomas (TCLs) are limited and treatment resistance to histone deacetylase (HDAC) inhibitors often occurs. Polycomb protein EED is a key member of the polycomb ...

A global consortium led by Adaptvac ApS aims to design and test a new vaccine that could offer broad protection against several filoviruses, including Zaire ebolavirus, Sudan ebolavirus and Marburg ...

T-cell therapy has been a game changer in the treatment of B-cell malignancies, although their manufacturing process is complex and needs lymphodepletion, thus limiting their use. Researchers from ...

Impact Therapeutics Inc. has disclosed new heteroaromatic and heterobicyclic compounds acting as Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of ...